The Indiana University School of Medicine has nine campuses throughout Indiana; the principal research and medical center is located on the Indiana University – Purdue University Indianapolis campus in Indianapolis.

During the past decade, Indiana University School of Medicine conducted 133 clinical trials. In the 10-year time frame, 133 clinical trials started and 61 clinical trials were completed, i.e. on average, 45.9% percent of trials that started reached the finish line to date. In the past 5 years, 59 clinical trials started and 37 clinical trials were completed. i.e. 62.7% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Indiana University School of Medicine" #1 sponsor was "Indiana University" with 39 trials, followed by "Eli Lilly and Company" with 17 trials sponsored, "Indiana University School of Medicine" with 8 trials sponsored, "Gilead Sciences" with 7 trials sponsored and "Washington University School of Medicine" with 7 trials sponsored. Other sponsors include 165 different institutions and companies that sponsored additional 131 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Indiana University School of Medicine" #1 collaborator was "Indiana University School of Medicine" with 6 trials as a collaborator, "Merck Sharp & Dohme LLC" with 6 trials as a collaborator, "National Institute on Aging (NIA)" with 6 trials as a collaborator, "Alzheimer's Association" with 5 trials as a collaborator and "Eli Lilly and Company" with 4 trials as a collaborator. Other collaborators include 161 different institutions and companies that were collaborators in the rest 125 trials.

According to Clinical.Site data, the most researched conditions in "Indiana University School of Medicine" are "Alzheimer's Disease" (13 trials), "HIV Infections" (7 trials), "Alzheimer Disease" (6 trials), "Dementia" (5 trials) and "Obesity" (5 trials). Many other conditions were trialed in "Indiana University School of Medicine" in a lesser frequency.

Most popular intervention types in "Indiana University School of Medicine" are "Drug" (154 trials), "Other" (31 trials), "Device" (20 trials), "Biological" (11 trials) and "Behavioral" (8 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (57 trials), "Solanezumab" (5 trials), "Bevacizumab" (4 trials), "Lecanemab" (4 trials) and "Gantenerumab" (3 trials). Other intervention names were less common.

The vast majority of trials in "Indiana University School of Medicine" are 218 trials for "All" genders, 22 trials for "Female" genders and 6 trials for "Male" genders.

Currently, there are NaN active trials in "Indiana University School of Medicine". undefined are not yet recruiting, 46 are recruiting, 26 are Active, not recruiting, and 5 are Enrolling by invitation. In total, there were 137 completed trials in Indiana University School of Medicine, 1 suspended trials, and 16 terminated clinical trials to date.

Out of the total trials that were conducted in Indiana University School of Medicine, 25 "Phase 1" clinical trials were conducted, 63 "Phase 2" clinical trials and 80 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 9 trials, and there were also 42 trials that are defined as “Not Applicable".